Delivery Order SPE2DR25D3301-SPE2DR26F18XC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,697.07 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes with a firm fixed price. The award was made on December 4, 2025, with an ultimate completion date of December 5, 2025, and involves no set-aside designation. Performance will occur at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $30,542.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Prolia 60 mg/ml syringe. This non-set-aside contract represents a single delivery order placed under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency has awarded a delivery order valued at $16,378.07 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. This non-competitive delivery order, issued on September 24, 2025, with completion targeted for September 25, 2025, represents a firm fixed price transaction under an existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location, leveraging its...
- The Defense Logistics Agency awarded a delivery order valued at $10,054.74 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of November 21, 2025. This competitive award, issued on November 20, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $26,886.29 by the Defense Logistics Agency (DLA) on October 23, 2025, with an ultimate completion date of October 24, 2025. The order is for Prolia 60 mg/ml syringes and represents a firm fixed price, competitively awarded contract with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $32,625.43 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, non-set-aside contract executed on August 19, 2025, with performance to take place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $60,897.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, with an ultimate completion date of December 5, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. The delivery order is issued under AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 15, 2025, for Prolia 60 mg/mL syringes valued at $12,957.22. The contract employs firm fixed pricing with an ultimate completion date of September 16, 2025, and was competitively awarded without set-aside designation. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $7,575.13 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Prolia 60 mg/ml syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The delivery is scheduled for completion by October 23, 2025, with performance taking place at...
- The Defense Logistics Agency awarded a delivery order valued at $11,037.94 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of December 8, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F18XCDelivery Order
The Defense Logistics Agency awarded a $111,834.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes on December 3, 2025, with an ultimate completion date of December 4, 2025. This is a non-set-aside competitive award issued under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. This delivery order represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with the Defense Logistics Agency. The company maintains a prime indefinite delivery contract valued at $999,999,999 and expiring in December 2026 that enables it to supply a comprehensive range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains in support of global military healthcare programs. The award of Prolia, a bone health medication, demonstrates the breadth of the company's federal pharmaceutical distribution portfolio, which includes specialty medications, brand-name and generic drugs, vaccines, and associated medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $111.8k | 12/2/25 |